Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join 4SC AG
News Jan 17, 2015
4SC AG has announced that Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky have been appointed as new members of its Supervisory Board.
Since 2006, Prof. Dr. Rübsamen-Schaeff has acted as Managing Director and CEO of AiCuris GmbH, a German biopharma company founded by her. In this capacity, she was responsible, among other things, for securing a licensing deal with US pharmaceutical company Merck with a total value of up to EUR 442 million plus royalties.
From 1994 to 2006 she held senior research positions at Bayer AG, Leverkusen, first as Vice President and Head of Antiviral Research from 1994 to 2001, later as Senior Vice President and Global Head of Bayer's Anti-Infective Research.
After obtaining a degree and doctorate in chemistry and working as a guest scientist at various international institutions including the US-universities Harvard and Cornell, she was Scientific and Managing Director at the Institute of Biomedical Research Georg-Speyer-Haus in Frankfurt (now Institute for Tumor Biology and Experimental Therapy) for six years.
In 1988 she was appointed as Professor of Biochemistry and Virology at the University of Frankfurt. In 2014 she was appointed as member of the Board of Partners and of the Supervisory Board of German pharmaceutical and chemical group Merck KGaA, Darmstadt, also acting as Chair of the company's Research Council since then.
Joerg von Petrikowsky has more than 30 years of experience as an auditor and tax adviser focusing in particular on the auditing and advising of international pharmaceutical, medical technology and biotechnology companies. Working for Arthur Andersen (1984-2002) and Ernst & Young (2002-2013), he held various senior positions including Head of Life Sciences at Ernst & Young. On the Supervisory Board of 4SC, Mr. von Petrikowsky will act as Chairman of the Audit Committee and as the independent financial expert.
Both terms of office will initially run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for the financial year 2014. Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn who recently stepped down. Thus the Supervisory Board of 4SC AG chaired by Dr. Clemens Doppler again consists of six members.
Dr. Clemens Doppler, Chairman of the Supervisory Board of 4SC AG, comments: "We are very pleased that with Helga Rübsamen-Schaeff and Joerg von Petrikowsky we have been able to attract two highly competent and renowned individuals for the Supervisory Board of 4SC AG."
High Fruit and Veg Consumption May Reduce Breast Cancer RiskNews
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers from Harvard T.H. Chan School of Public Health.READ MORE
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Why Might Super-Tasters be at Higher Cancer Risk?News
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been tracked for about 20 years.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018